News Daily News Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure Michael O'Riordan December 30, 2025
News Daily News Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM L.A. McKeown April 15, 2025
News Conference News HFSA 2024 ‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM L.A. McKeown October 02, 2024
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC Heart Failure 2024 SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM Michael O'Riordan May 13, 2024
News Conference News ESC Heart Failure 2023 Could Copper Chelation Benefit HFrEF? TRACER-HF Offers Mixed Clues Shelley Wood May 25, 2023
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ACC 2021 ‘Enormous’ QoL Improvements With Mavacamten in HCM Shelley Wood May 15, 2021
News Daily News Mavacamten Successful in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Shelley Wood May 11, 2020